Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 14:4:5676.
doi: 10.1038/srep05676.

Liquiritigenin alleviates mechanical and cold hyperalgesia in a rat neuropathic pain model

Li Chen  1 , Wei Chen  1 , Xiao Qian  1 , Yun Fang  1 , Naijun Zhu  1
Affiliations

Liquiritigenin alleviates mechanical and cold hyperalgesia in a rat neuropathic pain model

Li Chen et al. Sci Rep. .

Abstract

This study assessed the potential antinociceptive effects of liquiritigenin, a plant-derived compound with transient receptor potential melastatin 3 blocking activity in a rat model of persistent neuropathic pain. Chronic constriction injury (CCI) to the sciatic nerve was induced in male Sprague-Dawley rats to model human peripheral neuropathic pain. Liquiritigenin (1, 3, or 9 mg/kg) was administered intraperitoneally to examine the effects on mechanical, thermal, and cold hyperalgesia using the von Frey test, plantar test, and cold plate test, respectively. A rotarod test was also conducted to examine motor function. Liquiritigenin dose dependently alleviated mechanical, thermal and cold hyperalgesia. In addition, daily repeated treatment with liquiritigenin did not demonstrate significant antinociceptive tolerance in the measures of hyperalgesia. Within the doses studied, liquiritigenin did not significantly affect motor performance. These results suggest that liquiritigenin may be potentially useful novel treatments for neuropathic pain.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Chemical structure of liquiritigenin.
Figure 2
Figure 2. Effect of liquiritigenin on the paw withdrawal thresholds as tested by von Frey test (n = 8 per group).
Filled symbols indicated data significantly different from vehicle-treated group.
Figure 3
Figure 3. Effect of liquiritigenin on the paw withdrawal latency as tested by plantar test (n = 8 per group).
Filled symbols indicated data significantly different from vehicle-treated group.
Figure 4
Figure 4. Effect of liquiritigenin on the paw withdrawal latency as tested by cold plate test (n = 8 per group).
Filled symbols indicated data significantly different from vehicle-treated group.
Figure 5
Figure 5. Effect of liquiritigenin on the rotarod performance in rats (n = 8 per group).
See this image and copyright information in PMC

References

    1. Bouhassira D., Lanteri-Minet M., Attal N., Laurent B. & Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136, 380–387 (2008). - PubMed
    1. Loeser J. D. & Treede R. D. The Kyoto protocol of IASP Basic Pain Terminology. Pain 137, 473–477 (2008). - PubMed
    1. Treede R. D. et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70, 1630–1635 (2008). - PubMed
    1. Attal N. et al. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 138, 343–353 (2008). - PubMed
    1. Attal N. et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13, 1153–1169 (2006). - PubMed